Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Sarclisa

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            Sarclisa (isatuximab) has been recommended in combination with pomalidomide and dexamethasone (pom-dex) for adult with relapsed/refractory multiple myeloma who have received three prior lines of treatment, and at least two prior therapies including lenalidomide and a proteasome inhibitor.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Sarclisa

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            SARCLISA™ in combination with pom-dex significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 27, 2020

            Details:

            Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex.

            Virtual BoothThe 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group.

            Contact the Supplier

            Lead Product(s): Encorafenib,Cetuximab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 01, 2020

            Details:

            Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabozantinib,Nivolumab

            Therapeutic Area: Oncology Product Name: Cabometyx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2021

            Details:

            Recommendation based on the Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) doubled progression-free survival and significantly improved overall survival and response rates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dinutuximab

            Therapeutic Area: Oncology Product Name: Qarziba

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: BeiGene

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belinostat

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Acrotech Biopharma

            Deal Size: $6.6 million Upfront Cash: $6.6 million

            Deal Type: Agreement April 06, 2020

            Details:

            The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.